Influenza is a serious viral infection with only two main treatment options, vaccination or antivirals e.g. oseltamivir (Tamilflu®). Both options have drawbacks, for instance, vaccination relies on “precast” virus strains, which in the US during 2004/2005 – 2016/17 offered only 10% and 60 % protection1. Furthermore, the global vaccination rate is low; pandemic (2009): maximum of approx. 25%2. The antiviral option works through the inhibition of viral neuraminidase, blocking release of the virus from host cells (respiratory mucosa). Moreover, there is evidence of increasing resistance to oseltamivir and other neuraminidase inhibitors.
Inhaled LASAG (D,L-lysine acetylsalicylate • glycine), an lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®) is suitable as an ingredient for inhalable aerosol, which creates a new approach against viral infections. In contrast to systemic approaches, only the inhaled administration of the drug turned out to be efficacious, since it efficiently delivers the drug in sufficient quantity to the infected epithelial cells of the lower respiratory tract. The compound inhibits the viral replication by interacting with proteins in the host cell. Technically, LASAG blocks the NFкB pathway by interacting with host cell proteins that are responsible for viral ribonucleoprotein transport out of the nucleus. By suppressing this transport path, virus replication is prevented. Since no virus related proteins are involved in the mechanism of action of LASAG, the development of resistance against LASAG by mutation of virus DNA is highly unlikely.
For more information on LASAG mode of action, please click on the following picture:
1 BCC Research, Wellesley MA USA
2 Morbidity and Mortality Weekly Report, CDC, USA